Browsing Pharmacy by Subject "factor VIII"
Now showing items 1-4 of 4
-
Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)
(JMIR Publications, 2016-12-07)Background: Hemophilia is an inherited bleeding disorder caused by a deficiency in a specific clotting factor. This results in spontaneous bleeding episodes and eventual arthropathy. The mainstay of hemophilia treatment ... -
Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol
(JMIR Publications, 2016-12-15)Background: Individual pharmacokinetic assessment is a critical component of tailored prophylaxis for hemophilia patients. Population pharmacokinetics allows using individual sparse data, thus simplifying individual ... -
Pharmacokinetic and economic implications when switching between hemophilia A treatments
(University of Waterloo, 2023-04-18)Hemophilia is a bleeding disorder in which the blood is unable to form clots, and is also classified as severe (defined as having an endogenous factor VIII [FVIII] concentration < 1 IU/dL, or 1%), moderate (1-5%) or mild ... -
Pharmacokinetic modelling of clinically relevant situations in the treatment of hemophilia A and B
(University of Waterloo, 2020-04-03)Hemophilia is a congenital bleeding disorder caused by deficiency of clotting factor VIII (FVIII; hemophilia A) or IX (FIX; hemophilia B). Severe hemophilia patients have less than 1% (or 1 IU/dL) of normal factor activity, ...